3 days Ago By ABMN Staff
Dyne Therapeutics, Inc. ( NASDAQ:DYN – Free Report ) – Equities research analysts at Chardan Capital cut their FY2024 EPS estimates for Dyne Therapeutics in a note issued to investors on Wednesday, November 13th. Chardan Capital analyst K.
Nakae now expects that the company will post earnings of ($3.14) per share for the year, down from their prior estimate of ($2.75).
Chardan Capital has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.
39) per share. Chardan Capital also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($2.73) EPS.
Dyne Therapeutics ( NASDAQ:DYN – Get Free Report ) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
71) by ($0.25). Check Out Our Latest Stock Report on Dyne Therapeutics Dyne Therapeutics Trading Up 3.
3 % DYN stock opened at $29.34 on Monday. The company has a market cap of $2.
99 billion, a PE ratio of -8.24 and a beta of 1.10.
The stock has a 50-day moving average price of $32.42 and a two-hundred day moving average price of $35.26.
Dyne Therapeutics has a 12-month low of $10.03 and a 12-month high of $47.45.
Insider Buying and Selling at Dyne Therapeutics In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,339 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.
45. Following the sale, the insider now directly owns 140,375 shares in the company, valued at $4,849,956.25.
The trade was a 1.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website .
Also, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.
50. Following the completion of the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40.
The trade was a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders sold a total of 176,257 shares of company stock valued at $6,193,718 in the last ninety days. Insiders own 20.77% of the company’s stock.
Institutional Trading of Dyne Therapeutics A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sei Investments Co. bought a new stake in Dyne Therapeutics in the first quarter valued at about $693,000.
Seven Eight Capital LP bought a new stake in shares of Dyne Therapeutics in the 1st quarter valued at approximately $516,000. Swiss National Bank lifted its stake in Dyne Therapeutics by 41.5% during the first quarter.
Swiss National Bank now owns 85,200 shares of the company’s stock worth $2,419,000 after purchasing an additional 25,000 shares during the last quarter. Mutual of America Capital Management LLC acquired a new position in Dyne Therapeutics in the second quarter worth $1,724,000. Finally, Vanguard Group Inc.
boosted its holdings in Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc.
now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. Institutional investors own 96.68% of the company’s stock.
Dyne Therapeutics Company Profile ( Get Free Report ) Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. See Also Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
